Horizon Pharma plc Presents New Data at 2017 ACR/ARHP Annual Meeting, Advances Clinical Understanding of KRYSTEXXA® (pegloticase injection) in Adults with Uncontrolled Gout

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/5/2026

1. KRG
2. SPY
3. ALAR
4. CCHGY
5. PRY:IM
6. PRYMY
7. SKA-B
8. PBA
9. CCH:LN
10. META

Go back to Horizon Pharma plc Presents New Data at 2017 ACR/ARHP Annual Meeting, Advances Clinical Understanding of KRYSTEXXA® (pegloticase injection) in Adults with Uncontrolled Gout

Horizon Pharma (HZNP) PT Raised to $21 at Jefferies; Reiterates Buy

November 7, 2017 8:34 AM EST

Jefferies raised its price target on Horizon Pharma (NASDAQ: HZNP) to $21.00 (from $16.00) while maintaining a Buy rating following the company's 3Q earnings report.

Including the upside from the Q3 results and expected shift in operating expenses from Q3 to Q4, Jefferies raised... More